The vaccine — called Vaxzevria and developed in partnership with the University of Oxford — has been one of the main Covid-19 vaccines worldwide, with more than 3 billion doses supplied since ...

The drive to develop a nasal spray against COVID-19 infection suffered a setback Tuesday after AstraZeneca and Oxford University said a trial produced disappointing results.

Background to the agreement with AstraZeneca Oxford Biomedica announced an 18 month supply agreement in September 2020 under a three year Master Supply and Development Agreement (“the Agreement ...

Britain's Oxford Biomedica announced an agreement to potentially make AstraZeneca's COVID-19 vaccine beyond 2022. It has already manufactured more than 100 million doses since 2020.

The scheme has delivered more than 152 million vaccine doses to over 137 countries and territories, including in 83 lower-middle income countries. 65% of the initial vaccine doses have been Oxford ...

Under the new agreement, manufacturing of vaccines at Oxford Biomedica's 84,000 sq. ft manufacturing facility, Oxbox, will be available to AstraZeneca on an as needed basis beyond 2022.

AstraZeneca and Oxford University have started developing a version of their coronavirus shot that targets omicron, as researchers study the efficacy of existing vaccines against the latest ...

Britain's Oxford Biomedica said on Friday it had signed a new three-year agreement to potentially make AstraZeneca's COVID-19 vaccine beyond 2022, but no volumes were defined in an indication of ...

A three-dose course of AstraZeneca's COVID-19 vaccine is effective against the rapidly-spreading Omicron coronavirus variant, the pharmaceutical company said on Thursday, citing data from an ...

AstraZeneca Plc said on Tuesday it is working with Oxford University to produce a vaccine for the Omicron coronavirus variant, joining other vaccine-makers who are looking to develop the variant ...